PRQR has been the subject of several other research reports. Chardan Capital began coverage on shares of ProQR Therapeutics NV in a research report on Monday, June 20th. They set a neutral rating and a $4.50 price target for the company. Zacks Investment Research raised shares of ProQR Therapeutics NV from a sell rating to a hold rating in a research report on Friday, September 23rd. JMP Securities reaffirmed a buy rating on shares of ProQR Therapeutics NV in a research report on Tuesday, September 6th. Finally, Janney Montgomery Scott initiated coverage on shares of ProQR Therapeutics NV in a research report on Wednesday, September 28th. They issued a neutral rating and a $7.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $14.15.
Shares of ProQR Therapeutics NV (NASDAQ:PRQR) traded down 1.88% during trading on Friday, hitting $6.25. 5,934 shares of the stock were exchanged. The company’s market cap is $145.91 million. The firm has a 50 day moving average of $6.42 and a 200-day moving average of $5.41. ProQR Therapeutics NV has a 12-month low of $3.48 and a 12-month high of $16.23.
ProQR Therapeutics NV (NASDAQ:PRQR) last announced its quarterly earnings results on Wednesday, August 17th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by $0.00. On average, analysts forecast that ProQR Therapeutics NV will post ($2.09) earnings per share for the current year.
An institutional investor recently raised its position in ProQR Therapeutics NV stock. Redmile Group LLC raised its stake in ProQR Therapeutics NV (NASDAQ:PRQR) by 5.2% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 581,638 shares of the biopharmaceutical company’s stock after buying an additional 28,925 shares during the period. Redmile Group LLC owned 2.49% of ProQR Therapeutics NV worth $2,815,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 39.21% of the company’s stock.
ProQR Therapeutics NV Company Profile
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).
Receive News & Ratings for ProQR Therapeutics NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics NV and related companies with MarketBeat.com's FREE daily email newsletter.